Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review protocol|
|Author:||Dabrow Woods, A.|
|Citation:||JBI Database of Systematic Reviews and Implementation Reports, 2014; 12(1):74-89|
|Publisher:||Joanna Briggs Institute|
|Anne Dabrow Woods, Renee Giometti, Susan Weeks|
|Abstract:||Review question/objective - In adult intensive care unit patients experiencing alcohol withdrawal, does the use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy decrease delirium severity more effectively than benzodiazepine-based therapy alone? The objective of the systematic review is to examine the best available evidence of the clinical effectiveness of dexmedetomidine as an adjuvant to benzodiazepine-based therapy versus benzodiazepine-based therapy alone, in decreasing delirium severity associated with alcohol withdrawal in adult intensive care unit patients over the age of 18 years.|
|Keywords:||alcohol withdrawal syndrome; benzodiazepine-based therapy; delirium; dexmedetomidine; intensive care unit|
|Rights:||Copyright status unknown|
|Appears in Collections:||Translational Health Science publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.